How to buy Replimune Group stock

Replimune Group, Inc is a biotechnology business based in the US. Replimune Group shares (REPL) are listed on the NASDAQ and all prices are listed in US Dollars. Replimune Group employs 122 staff and has a market cap (total outstanding shares value) of 0.00.

Replimune Group share price

Use our graph to track the performance of REPL stocks over time.

Replimune Group shares at a glance

• Key figures

Information last updated 2021-04-21.

52-week range	$11.75 - $54.85
50-day moving average	$32.05
200-day moving average	$38.94
Wall St. target price	$56.30
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.01

Buy Replimune Group shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Replimune Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Replimune Group, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Replimune Group financials

Gross profit TTM	$0
Return on assets TTM	-11%
Return on equity TTM	-21.06%
Profit margin	0%
Book value	$11.13
Market capitalisation	$1.4 billion

TTM: trailing 12 months

Shorting Replimune Group shares

There are currently 3.0 million Replimune Group shares held short by investors – that's known as Replimune Group's "short interest". This figure is 14.7% up from 2.6 million last month.

There are a few different ways that this level of interest in shorting Replimune Group shares can be evaluated.

Replimune Group's "short interest ratio" (SIR)

Replimune Group's "short interest ratio" (SIR) is the quantity of Replimune Group shares currently shorted divided by the average quantity of Replimune Group shares traded daily (recently around 427519.48051948). Replimune Group's SIR currently stands at 6.93. In other words for every 100,000 Replimune Group shares traded daily on the market, roughly 6930 shares are currently held short.

However Replimune Group's short interest can also be evaluated against the total number of Replimune Group shares, or, against the total number of tradable Replimune Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Replimune Group's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Replimune Group shares in existence, roughly 60 shares are currently held short) or 0.133% of the tradable shares (for every 100,000 tradable Replimune Group shares, roughly 133 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Replimune Group.

Find out more about how you can short Replimune Group stock.

Replimune Group share dividends

We're not expecting Replimune Group to pay a dividend over the next 12 months.

Replimune Group share price volatility

Over the last 12 months, Replimune Group's shares have ranged in value from as little as $11.75 up to $54.85. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Replimune Group's is 2.517. This would suggest that Replimune Group's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Replimune Group overview

Replimune Group, Inc. , a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Frequently asked questions

What percentage of Replimune Group is owned by insiders or institutions?
Currently 9.977% of Replimune Group shares are held by insiders and 94.285% by institutions. How many people work for Replimune Group?
Latest data suggests 122 work at Replimune Group. When does the fiscal year end for Replimune Group?
Replimune Group's fiscal year ends in March. Where is Replimune Group based?
Replimune Group's address is: 500 Unicorn Park, Woburn, MA, United States, 01801 What is Replimune Group's ISIN number?
Replimune Group's international securities identification number is: US76029N1063 What is Replimune Group's CUSIP number?
Replimune Group's Committee on Uniform Securities Identification Procedures number is: 76029N106